Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates Pharmaceutical TechnologyBMS shared Phase III data for mezigdomide and Phase I data for a CAR-T therapy at this year's EHA conference.OncologyRead full story pharminent June 17, 2026 (Last updated: June 17, 2026) Pharmaceutical Technology BMS shared Phase III data for mezigdomide and Phase I data for a CAR-T therapy at this year’s EHA conference. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA, Moderna appear aligned on mRNA flu shot heading into adcommNext: Altaris to acquire Simulations Plus in $375m all-cash deal Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
